Abstract
Different statutes govern the regulation of drug and biologic products in the United States. Whereas both are subject to the Food, Drug, and Cosmetic Act of 1948, biologic products are mainly regulated by the Public Health Service Act of 1944. The differences in the regulation of drug and biologic products are mainly owing to the basic premise that most drug products have a known structure and are chemically synthesized, whereas biologic products are derived from living sources (such as humans, animals, plants, and micro-organisms), may not have a completely defined structure, tend to be heat-sensitive, and are prone to microbial contamination. According to the regulations, a biologic product is any virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product applicable to the prevention, treatment, or cure of disease or injuries to humans (http://www.fda.gov/cber/faq.htm) (1). Oncologic products classified as biologics include preventative and therapeutic vaccines, somatic cell and gene therapy, monoclonal antibodies, immunotoxins, radioimmunotherapy, recombinant proteins (e.g., cytokines, growth factors, and fusion proteins), and most other biotechnology-derived products.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Food and Drug Administration. 21 Code Federal Regulations 600.3(h).
Serabian M, Pilaro AM. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond. Toxicol Pathol 1999; 27: 27–31.
Green JD, Black LE. Overview status of preclinical safety assessment for immunomodulatory biopharmaceuticals. Hum Exp Toxicol 2000; 19: 208–212.
Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). EndocrRelat Cancer 2002; 9: 75–85.
Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, February, 1997.
Pilaro AM, Serabian MA. Preclinical development strategies for novel gene therapeutic products. Toxicol Pathol 1999; 27: 4–7.
Martin A, Frey-Vasconcells J. A view on ancillary products for the emerging area of tissue engineered products. Regul Affairs Focus 1999; June:16–17.
Guidance for Industry: ICH S6 Preclinical Evaluation of Biotechnology-Derived Pharmaceuticals, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, July, 1997.
Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunol 2002; 25: 97–138.
Razzaque A, Dye E, Puri RK. Characterization of tumor vaccines during product development. Vaccine 2000; 19: 644–647.
Guidance for Industry: ICH M3 Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, November, 2000.
FDA Guidance Concerning Demonstration of Comparability of Human Biologcial Products, including Therapeutic Biotechnology-Derived Products, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, April, 1996.
Black LE, Bendele AM, Bendele RA, Zack PM, Hamilton M. Regulatory decision strategy for entry of a novel biological therapeutic with a clinically unmonitorable toxicity into clinical trials: pre-IND meetings and a case example. Toxicol Pathol 1999; 27: 22–26.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Laurençot, C.M., Roy, D., Andrews, P.A. (2004). Nonclinical Testing for Oncology Biologic Products. In: Teicher, B.A., Andrews, P.A. (eds) Anticancer Drug Development Guide. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-739-0_15
Download citation
DOI: https://doi.org/10.1007/978-1-59259-739-0_15
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-9841-7
Online ISBN: 978-1-59259-739-0
eBook Packages: Springer Book Archive